Business Model
Business Model
Mucosis intends to bring its candidate vaccines into early phase clinical development. For late stage clinical development and marketing of our vaccines, we intend to further increase the value of our programs and products by collaborating with industrial partners that have established a strong regulatory and business presence in the vaccine field.
Drivers
Products with competitive advantages.
We have selected vaccine candidates that improve the currently available vaccines by means of patient friendliness and efficacy, and for which predictive animal models exist and/or correlates of protection in humans are documented. The availability of models and correlates of protection shorten development timelines, reduce development risks and increase the chance for our products to hit the market. Our lead product FluGEM™ is an intranasal influenza vaccine. We also run various vaccine research programs to identify new vaccine leads that can fill the product pipeline.
Leveraging the value of our technology by licensing.
We have developed a plug & play vaccine technology that can contribute to a broad spectrum of vaccine products. We will license the technology to third parties for use in their in-house vaccine development programs. This will generate short term licensing revenue and future revenue from royalty on sales of the products that are developed with our technology. These revenues will be used to accelerate the development of Mucosis’s in-house vaccine programs.